OBJECTIVE: The prevalence of fluoroquinolone (FQ) resistance in Escherichia coli has increased markedly in recent years. Despite the important role of gastrointestinal tract colonization with FQ-resistant E. coli (FQREC), the prevalence of and risk factors for FQREC colonization among the general hospitalized patient population have not been described, to our knowledge. The objective of this study was to identify the prevalence of and risk factors for FQREC colonization among hospitalized patients. DESIGN: Three-year case-control study. Case patients (ie, all subjects with FQREC colonization) were compared with control patients (ie, all subjects without FQREC colonization). SETTING: Two large medical centers within an academic health system. PARTICIPANTS: All patients hospitalized at the 2 study hospitals. MAIN OUTCOME MEASURE: Three annual fecal surveillance surveys were conducted. All patients colonized with FQREC (levofloxacin minimum inhibitory concentration, >or=8 microg/mL) were identified. RESULTS: Of the 774 subjects, 89 (11.5%) were colonized with FQREC. Although there was a significant association between prior FQ use and FQREC colonization on bivariable analysis (odds ratio [OR], 2.02 [95% confidence interval {CI}, 1.14-3.46]; P=.01), there was statistically significant effect modification by year of study (P=.005). In multivariable analyses, after controlling for the hospital and for the duration of hospitalization prior to sampling, the association between FQ use and FQREC colonization was as follows: adjusted OR (aOR), 0.97 (95% CI, 0.29-3.23) in 2002; aOR, 1.41 (95% CI, 0.57-3.50) in 2003; and aOR, 9.87 (95% CI, 3.67-26.55) in 2004. CONCLUSIONS: The association between prior FQ use and FQREC colonization varied significantly by study year, suggesting that the clinical epidemiology of resistant organisms may change over time. Furthermore, in the context of recent work showing significant changes in FQREC prevalence as well as changes in FQ resistance mechanisms (specifically, efflux overexpression) over the same time period, these results suggest a previously unrecognized complexity in the relationship between the clinical and molecular epidemiology of FQ resistance.
OBJECTIVE: The prevalence of fluoroquinolone (FQ) resistance in Escherichia coli has increased markedly in recent years. Despite the important role of gastrointestinal tract colonization with FQ-resistant E. coli (FQREC), the prevalence of and risk factors for FQREC colonization among the general hospitalized patient population have not been described, to our knowledge. The objective of this study was to identify the prevalence of and risk factors for FQREC colonization among hospitalized patients. DESIGN: Three-year case-control study. Case patients (ie, all subjects with FQREC colonization) were compared with control patients (ie, all subjects without FQREC colonization). SETTING: Two large medical centers within an academic health system. PARTICIPANTS: All patients hospitalized at the 2 study hospitals. MAIN OUTCOME MEASURE: Three annual fecal surveillance surveys were conducted. All patients colonized with FQREC (levofloxacin minimum inhibitory concentration, >or=8 microg/mL) were identified. RESULTS: Of the 774 subjects, 89 (11.5%) were colonized with FQREC. Although there was a significant association between prior FQ use and FQREC colonization on bivariable analysis (odds ratio [OR], 2.02 [95% confidence interval {CI}, 1.14-3.46]; P=.01), there was statistically significant effect modification by year of study (P=.005). In multivariable analyses, after controlling for the hospital and for the duration of hospitalization prior to sampling, the association between FQ use and FQREC colonization was as follows: adjusted OR (aOR), 0.97 (95% CI, 0.29-3.23) in 2002; aOR, 1.41 (95% CI, 0.57-3.50) in 2003; and aOR, 9.87 (95% CI, 3.67-26.55) in 2004. CONCLUSIONS: The association between prior FQ use and FQREC colonization varied significantly by study year, suggesting that the clinical epidemiology of resistant organisms may change over time. Furthermore, in the context of recent work showing significant changes in FQREC prevalence as well as changes in FQ resistance mechanisms (specifically, efflux overexpression) over the same time period, these results suggest a previously unrecognized complexity in the relationship between the clinical and molecular epidemiology of FQ resistance.
Authors: Rhonda D Quain; Todd D Barton; Neil O Fishman; Mark G Weiner; Ebbing Lautenbach Journal: Int J Antimicrob Agents Date: 2005-10 Impact factor: 5.283
Authors: Ebbing Lautenbach; Anthony D Harris; Eli N Perencevich; Irving Nachamkin; Pam Tolomeo; Joshua P Metlay Journal: Antimicrob Agents Chemother Date: 2005-02 Impact factor: 5.191
Authors: Ebbing Lautenbach; Joshua P Metlay; Warren B Bilker; Paul H Edelstein; Neil O Fishman Journal: Clin Infect Dis Date: 2005-08-24 Impact factor: 9.079
Authors: D L Paterson; L Mulazimoglu; J M Casellas; W C Ko; H Goossens; A Von Gottberg; S Mohapatra; G M Trenholme; K P Klugman; J G McCormack; V L Yu Journal: Clin Infect Dis Date: 2000-03 Impact factor: 9.079
Authors: Jennifer H Han; Warren B Bilker; Irving Nachamkin; Pam Tolomeo; Xiangqun Mao; Neil O Fishman; Ebbing Lautenbach Journal: Infect Control Hosp Epidemiol Date: 2013-08-23 Impact factor: 3.254
Authors: Jennifer H Han; Kei Kasahara; Paul H Edelstein; Warren B Bilker; Ebbing Lautenbach Journal: Antimicrob Agents Chemother Date: 2012-08-13 Impact factor: 5.191
Authors: Jennifer H Han; Charles Garrigan; Brian Johnston; Irving Nachamkin; Connie Clabots; Warren B Bilker; Evelyn Santana; Pam Tolomeo; Joel Maslow; Janice Myers; Lesley Carson; Ebbing Lautenbach; James R Johnson Journal: Diagn Microbiol Infect Dis Date: 2016-11-28 Impact factor: 2.803
Authors: Jennifer H Han; Brian Johnston; Irving Nachamkin; Pam Tolomeo; Warren B Bilker; Xiangqun Mao; Connie Clabots; Ebbing Lautenbach; James R Johnson Journal: Antimicrob Agents Chemother Date: 2014-09-08 Impact factor: 5.191